{"contentid": 488026, "importid": NaN, "name": "Boehringer drops development of a COVID-19 candidate", "introduction": "Boehringer Ingelheim today announced that it has decided to discontinue treatment in the Phase II trial of a novel, first-in-class compound for reducing the risk or severity of acute respiratory distress syndrome (ARDS) in patients hospitalized for COVID-19 and requiring non-invasive oxygen support.", "content": "<p>Boehringer Ingelheim today announced that it has decided to discontinue treatment in the Phase II trial of a novel, first-in-class compound for reducing the risk or severity of acute respiratory distress syndrome (ARDS) in patients hospitalized for COVID-19 and requiring non-invasive oxygen support.</p>\n<p>This decision by the German family-owned is based on the recommendation of the trial&rsquo;s independent Data Monitoring Committee after an interim look at unblinded safety and efficacy data showing a clear lack of benefit for use of BI 764198 in patients hospitalized for COVID-19 and needing oxygen support.</p>\n<h2><strong>Will continue other trial programs</strong></h2>\n<p>&ldquo;The discontinuation of this Phase II trial underscores how challenging it is to develop treatments to help patients with COVID-19-induced ARDS. We believe that beyond vaccines, effective treatments for COVID-19 and its complications are urgently needed and we will continue other trial programs including the research and development of a SARS-CoV-2 neutralizing antibody that can be administered via inhalation,&rdquo; said Dr Mehdi Shahidi, corporate senior vice president medicine and chief medical officer, Boehringer Ingelheim.</p>\n<p>Boehringer says it remains involved in various initiatives to fight COVID-19 and help save patients&rsquo; lives, leveraging the company&rsquo;s expertise in antibody development and production, vascular and respiratory disease, combined with a focus on patient-centric innovation. This includes the research and development of COVID-19 antibodies that can neutralize the virus, the development of therapies to prevent blood clots and diagnostic tests to support virus identification.</p>\n<p>A final assessment of the efficacy and safety of the compound will be published in the coming months, following review of the full trial data set.</p>", "date": "2021-03-12 16:11:00", "meta_title": "Boehringer drops development of a COVID-19 candidate", "meta_keywords": "Boehringer Ingelheim, BI 765 198, Phase II, COVID-19, Discontinued", "meta_description": "Boehringer drops development of a COVID-19 candidate", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-12 16:10:18", "updated": "2021-03-12 16:18:10", "access": NaN, "url": "https://www.thepharmaletter.com/article/boehringer-drops-development-of-a-covid-19-candidate", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "boehringer_building_large.jpg", "image2id": "boehringer_building_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Infectious diseases, Respiratory and Pulmonary", "topic_tag": "Coronavirus, Drug Trial, Focus On, Research", "geography_tag": "Germany", "company_tag": "Boehringer Ingelheim", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-12 16:11:00"}